endogenous glp 1 GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 receptor agonists and DPP-4

I wrote about stress, oxidative stress and glutathione in my most recent book: Master Your Stress Reset Your Health

Here are 8 potential reasons why not to prescribe Lixisenatide: 1- this is only one small study and only one dose was tested, 2- Lixisenatide is not currently available at pharmacies, 3- the weight loss associated with this GLP-1 is not desirable in many cases of Parkinsons disease where weight loss is an issue, 4- non-motor outcomes did not change as in other trials, and this will need to be better explained

[1] [4] Safety Considerations After Gallbladder Removal When considering Wegovy for patients who have undergone cholecystectomy, clinicians must evaluate the reason for gallbladder removal and ensure adequate post-operative recovery

IV therapy is more expensive because it requires clinical staff, sterile compounding and one-on-one care